Pompe disease is caused by a deficiency of the lysosomal enzyme acid α-glucosidase (GAA). GAA is synthesized as a 110-kDa precursor containing N-linked carbohydrates modified with mannose 6-phosphate groups. Following trafficking to the lysosome, presumably via the mannose 6-phosphate receptor, the 110-kDa precursor undergoes a series of complex proteolytic and N-glycan processing events yielding major species of 76-and 70-kDa. During a detailed characterization of human placental and recombinant human GAA, we found that the peptides released during proteolytic processing remain tightly associated with the major species. 
INTRODUCTION
Lysosomal acid α-glucosidase (GAA; EC 3.2.1.3) is an exo-1,4 and 1,6-α−glucosidase that hydrolyzes glycogen to glucose. The cDNA for GAA encodes a protein of 952 amino acids with a predicted molecular mass of 105-kDa (1) . The newly synthesized precursor has an aminoterminal signal peptide for cotranslational transport into the lumen of the endoplasmic reticulum where it is N-glycosylated at seven glycosylation sites, resulting in a glycosylated precursor with an apparent molecular weight of 110-kDa.
The intracellular processing of GAA has previously been investigated (2) (3). These authors proposed after transport through the Golgi complex and targeting to the endosome/lysosome, the 110-kDa precursor is proteolytically processed at the amino-terminus, resulting in a 95-kDa intermediate with a sequence beginning at amino acid 122. Prior to this study, the 95-kDa intermediate was proposed to be proteolytically processed to a 76-kDa form, which was believed to occur between amino acids 816 and 881 (3) . The 76-kDa form is then proteolytically processed at the amino-terminus at amino acid 204 to give the 70-kDa mature form (3) . The nomenclature used for the processed forms of GAA is based on apparent molecular mass as determined by SDS-PAGE.
The identities of the proteases involved in the maturation of GAA have never been established. GAA has been purified from many different tissues such as bovine testis (4), rat liver (5), pig liver (6), human liver (7), rabbit muscle (8) , human heart (9), human urine (10) , and human placenta (2) , (11) . The predominant species observed are the 76-and 70-kDa mature forms. The fate of the cleaved fragments is unknown. Several reports have noted the presence of small polypeptides in highly purified preparations of the 76-and 70-kDa forms (12) (13) (14) . It was suggested the small polypeptides might be contaminants, degradation products, or a previously described GAA activation protein (15) .
Proteolytic processing appears to be required for optimal activity towards the natural substrate glycogen. There is a sevenfold to tenfold increase in the affinity of the 76-/70-kDa species for glycogen as compared with the 110-kDa precursor (16, 17) . In addition to the proteolytic maturation of the GAA peptide backbone, there is extensive processing of the carbohydrate chains. GAA is targeted to the lysosomes by the mannose-6-phosphate receptor, but analysis of the carbohydrate chains from purified 76-/70-kDa GAA from human placenta revealed the absence of mannose-6-phosphate and additional carbohydrate processing (18) .
A deficiency of acid α-glucosidase causes Pompe disease, which results in the accumulation of glycogen in lysosomes. Pompe disease is an autosomal recessive disorder that varies from a fatal infantile form to a more slowly debilitating adult onset form, reviewed in (19) .
Efforts are underway to develop enzyme replacement therapy for Pompe disease. Several similar but distinct transgenic (13, 16) or recombinant (17, 18) GAA preparations have been developed for this purpose. Several reports have demonstrated that enzyme replacement therapy using the 110-kDa precursor form of GAA degrades lysosomal glycogen in cultured Pompe fibroblasts and GAA knockout mice (13, 16, 18) . Although the 110-kDa form of GAA has been administered therapeutically, it is the mature forms that are found in the lysosome and it is the mature forms which are most active towards the glycogen substrate.
In this report, we demonstrate that proteolytically processed GAA purified from human placenta consists of four different peptides processed from a single chain precursor. We demonstrate that recombinant 110-kDa precursor GAA is internalized by Pompe fibroblasts via
Buffers
Buffer A contained 25 mM Tris-HCl, pH 6.5, 2 mM PMSF, 2 mM Benzamidine, 50 mM NaCl, and 0.25% Triton. Buffer B contained 20 mM Tris-HCl, pH 6.5, 1 mM CaCl 2 , 1 mM MnCl 2 , and 500 mM NaCl. Buffer C contained 20 mM Bis-Tris-HCl, pH 5.5. Buffer D contained 20 mM Bis-Tris-HCl pH 5.5, 500 mM NaCl. Buffer E contained 3 M (NH 4 ) 2 SO 4 , 75 mM Tris-HCl pH 6.5. Buffer F contained 1 M (NH 4 ) 2 SO 4 , 25 mM Tris pH 6.5. Buffer G contained 50 mM NaH 2 PO 4 pH 6.5, 20 mM NaCl. Buffer H contained 40 mM Tris-HCl pH 8.3, 39 mM Glycine, 20% MeOH, and 0.04% SDS. Buffer I contained 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM CaCl 2 , 0.05% Tween 20. Buffer J contained 20 mM NaH 2 PO 4 pH 6.5.
Cell lines
Chinese hamster ovary CHO-K1 cells were obtained from American Type Culture Collection (Manassas, VA). The Pompe fibroblast cell line GM00248 was obtained from Coriell Cell Repositories (Camden, NJ). To our knowledge, the GAA mutation in this cell line is not known.
Purification of hamster acid α-glucosidase from Chinese hamster ovary cells
Step 1: Harvest cells and cell lysis -CHO-K1 cells were expanded to five hundred 1700 cm 2 roller bottles in media containing DMEM/1x GS, 10% dialyzed fetal bovine serum, 25 µM MSX, 5% CO 2 at 37 o C. Each bottle was rinsed with 40 ml DPBS then rolled for 30 min at 37 o C in the presence of 40 ml of cell lysis buffer A. The cell lysate was clarified with a 10" 0.2 µm Opticap filter (Millipore) and stored at -20 o C.
Step 2: Concanavalin A -The clarified cell lysate was adjusted to 1 mM MnCl 2 and 1 mM CaCl 2 and applied to a Concanavalin A column (5.0 x 18 cm) equilibrated with buffer B at 50 ml/min. The column was washed with ~ 7 column volumes of buffer B and step eluted with buffer B containing 0.25 M α-methylglucoside. Three 1 liter fractions were collected and pooled.
Step 3 were collected and assayed for acid α-glucosidase activity and protein.
Step 4: DEAE-Sepharose FF -Two activity peaks eluted from the Superdex 200 column. The first activity peak contained 25% of the recovered activity. Because no additional purity was gained in the first activity peak, we could not isolate GAA from that peak. However, the second activity peak to elute, which contained 75% of the recovered activity, was significantly enriched for GAA. The second peak was pooled and diluted with 2 volumes of buffer C and applied to a DEAE-Sepharose FF column (1.6 x 10 cm) equilibrated with buffer C at 10 ml/min. After washing with 5 column volumes, the column was developed with a 30 column volume gradient from 0.0 to 0.3 M NaCl in buffer C. Fractions of 10 mls were collected and assayed for acid α-glucosidase activity and protein.
Step 5: Reverse Phase Chromatography -Reverse phase narrow bore HPLC was performed using a Michrom BioResources Ultra-fast Micro Protein Analyzer (Michrom BioResources, Auburn, CA). An aliquot (~50 µg) of Chinese hamster acid α-glucosidase (DEAE fraction) was diluted 1:1 with "magic mix" (4) 
Purification of mature acid α-glucosidase from human placenta
The purification of human placental acid α-glucosidase was based on previously reported methods (14, 18) .
Step 1: Homogenization of Tissue -Three human placentas were diced after the connective tissue had been removed and added to a Waring blender. An equal weight of ice-cold 25 mM NaCl was added and the tissue was homogenized for 3 minutes. The homogenate was then centrifuged at 38,400 x g for 30 minutes at 4 o C. The supernatant was clarified with a 4"
Opticap 0.22 µm filter (Millipore).
Step 2: Concanavalin A -The clarified supernatant was adjusted to 1 mM MnCl 2 and 1 mM CaCl 2 and applied to a Concanavalin A column (2.6 x 20 cm) equilibrated with buffer B at 9 ml/min. The column was washed with ~10 column volumes of buffer B and step eluted with buffer B containing 0.25 M α-methylglucoside. Three 0.25 liter fractions were collected and pooled.
Step Step 4: Affinity Chromatography on Superdex 200 -Peak fractions from the PhenylSepharose elution were concentrated to 10 mls in a 50 ml stirred ultra-filtration cell (Amicon), using a 30,000 NMWL, polyethersulfone membrane (Millipore). The sample was then applied to a Superdex 200 column (2.6 x 65 cm) preequilibrated in buffer G at 2.5 ml/min. Fractions of 6 mls were collected and assayed for acid α-glucosidase activity and protein.
Step 5: Superose 6-A peak fraction from Superdex 200 was applied to a Superose 6 column (10 x 30 cm) equilibrated with buffer G at 2 ml/min. Fractions of 2 ml were collected and assayed for acid α-glucosidase activity and protein.
Recombinant human precursor and intermediate GAA (rhGAA)
Precursor and intermediate rhGAA were produced using CHO cells transfected with a vector containing a full length human GAA cDNA, following the method previously described (22) . Based on the previously described method for the purification of rhGAA (23), rhGAA was purified from the CHO-conditioned media as follows: CHO cell culture harvest is clarified by sequential direct-flow filtration using a polyethersulfone prefilter followed by a Whatman 
Preparation of Recombinant Human GlcNAc-phosphotransferase
A detailed description of the preparation GlcNAc-phosphotransferase is in preparation.
Briefly, a production cell line secreting recombinant soluble human GlcNAc-phosphotransferase was generated by transfection of CHO cells with a 'double gene' expression vector in pEE14.1/pEE6.1 (Lonza Biologics, Portsmouth, NH) containing modified human GlcNAcphosphotransferase α/β−subunit sequences and the native γ−subunit sequence. The α/β-subunit cDNA contained four modifications of the native sequence. First, the N-terminal signal-anchor sequence was replaced by a signal peptide derived from mouse immunoglobulin kappa light chain. Second, the C-terminal transmembrane sequence was deleted by truncation following amino acid 1209. Third, the sequence at the α/β-cleavage site, (amino acids 924-929), was replaced by the sequence RARYKR introducing a recognition site for the processing enzyme furin. Fourth, a twelve amino acid epitope sequence recognized by monoclonal antibody HPC4
was added following the signal peptide cleavage site. The γ−subunit sequence was unmodified from the native sequence.
To prepare recombinant soluble GlcNAc-phosphotransferase, the production cell line was cultured in DMEM containing 10% fetal bovine serum in roller bottles incubated at 37°C in a 5% CO 2 atmosphere. Conditioned media was chromatographed on a column of HPC4 immobilized at 5 mg/ml on NHS-Sepharose (Amersham Pharmacia, Piscataway, NJ). Soluble
GlcNAc-phosphotransferase was eluted with 100 mM NaCl, 50 mM Tris-HCl, pH 7.2 containing 5 mM EGTA and 15 mM MgCl 2 . Following elution and buffer exchange into 150 mM NaCl, 50
mM NaAc, pH 6.5 containing 15 mM MgCl 2 GlcNAc-Phosphotransferase was stored at -80°C until use. The purified GlcNAc-phosphotransferase had a specific activity of approximately 10 micromole/hr-mg. A detailed description has been published in US patent 6,642,038.
Purification of highly phosphorylated recombinant human GAA (HP-rhGAA)
A detailed method for the production of HP-rhGAA will be described elsewhere (manuscript in preparation). Briefly, recombinant human GAA was expressed in CHO cells grown in the presence of kifunensine at 1 mg/L. Kifunensine selectively inhibits α-mannosidase I and causes the accumulation of Man 7-9 GlcNac 2 oligosaccharides on glycoproteins. A preparation containing the 110-, 95-and 76-kDa forms was purified from the conditioned media and the glycans containing terminal mannose were phosphorylated by treatment with UDP-Nacetylglucosamine: Lysosomal enzyme N-Acetylglucosamine-1-phosphotransferase (GlcNacphosphotransferase). The transfer of GlcNac-phosphate to terminal mannoses was performed at a GlcNac-phosphotransferase to GAA ratio of 1:10 (w/w). UDP-GlcNac was added to the reaction at 3 mM. The reaction was followed by the addition of 1% (w/w) NAcetylglucosamine-1-phosphodiester α-N-Acetylglucosaminidase (uncovering enzyme).
Uncovering enzyme removes the GlcNac to give mannose-6-phosphate. The 95-/76-kDa intermediates were separated from the 110-kDa precursor by Superdex 200 affinity chromatography.
Western blot analysis
Samples were boiled in 4x sample buffer (NuPage, Invitrogen) and applied to a 4-20%
Tris-Glycine SDS-PAGE pre-cast gel (Novex, Invitrogen) and run at 180 V for ~60 min in 25 mM Tris, 0.2 M Glycine. Proteins were transferred to PVDF membrane (Pierce) with a semi-dry blot apparatus (Bio-Rad) in buffer H at 20 V for 60 min. The membrane was blocked in 3% nonfat dry milk in buffer I for 30 min and then incubated with the designated antibody at 1 ug/ml in 3% milk in buffer I for 1 hr at room temperature. The membrane was washed 5X in buffer I
and then the secondary horse radish peroxidase-conjugated anti-mouse, anti-goat, or anti-rabbit antibody was applied at 1 ug/ml in 3% nonfat dry milk in buffer I for 1 hr at room temperature.
The membrane was washed 4 x in buffer I and then 4 x in buffer I without Tween 20. Acid α-glucosidase was visualized with the SuperSignal detection kit (Pierce).
Antibodies
Goat polyclonal antibody to human GAA (gt Anti-GAA) was produced by Ferrell Farms 
MALDI TOF MS analysis of reduced and non-reduced protein samples
Protein samples were mixed in a 1:1 ratio with saturated sinapinic acid matrix solution (50% of 0.1% trifluoroacetic acid/H 2 O and 50% acetonitrile) and one µl of the mixture applied to the sample target. The data were acquired in positive, linear mode on a Voyager DE PRO (Applied Biosystems) MALDI-TOF mass spectrometer. Singly-and doubly-charged molecular ions of bovine serum albumin (Sigma) were used to calibrate for the mass range of 20-140 kDa.
The singly charged molecular ions of insulin and apomyoglobin from calibration mixture 3
(Applied Biosystems) were used to calibrate the mass range of 2-20 kDa.
Capillary LC/MS analysis of reduced and non-reduced protein samples
Capillary LC/MS was performed on a Q-STARTOF mass spectrometer (Applied Biosystems) interfaced with an Ultimate capillary LC system (LC Packings). Protein separations were performed on a Vydac C4 reverse phase column (320 µm x 50 cm, Microtech Scientific) with a mobile phase of 1% formic acid in water (A) and acetonitrile (B). The flow rate was 4 µl/min. The mass spectra were acquired in the positive mode in range of m/z 800-3000. Protein reduction was performed by adding one µl of 10% β−mercaptoethanol to every 10 µl of protein sample. The samples were sonicated for 25 min and heated at 100 0 C for 1 min. before mass spectrometric analysis.
Capillary LC/MS/MS peptide mapping of protein tryptic digests
On-line capillary LC/MS/MS was performed on both Esquire LC (Bruker) and Q-STARTOF systems. Proteins were separated on a 320 µm x 15 cm (Microtech Scientific) Vydac C18 column, using chromatography conditions previously described. On both instruments, the two most intensive peaks with m/z greater than 350 were chosen for on-line MS/MS.
Amino-terminus micro-sequencing
Samples of reduced and non-reduced rhGAA and placental GAA were applied to a 4-20% or 6% Tris-Glycine SDS-PAGE gel (Invitrogen). Electrophoresis was performed at 150 volts for 1.2 hours. The proteins were transferred to a PVDF membrane using 10 mM CAPS, pH 
Fibroblast uptake of HP-rhGAA
For each time point, approximately 0.5 million Pompe fibroblasts (GM00248) in DMEM medium plus 10% FBS were incubated with 50 nM highly phosphorylated GAA prepared as described above. At designated time points, the cells were removed and washed 5 times with phosphate buffered saline and stored at -80°C. At 24 hours, the cells were washed and fresh media that did not contain GAA was added. After the final time point, all cell pellets were thawed and lysed simultaneously with 0.25% Triton. Cellular debris was pelleted and western blot analysis was performed on supernatants from each time point with several different antibodies to GAA. The blot was developed as described under "Western blot analysis."
RESULTS

Placental GAA Contains Low Molecular Weight Polypeptides Derived from GAA
GAA was purified from human placenta, using Concanavalin A Sepharose, Phenyl
Sepharose and Superdex 200 chromatography. The final step is affinity chromatography, which takes advantage of the retardation of GAA because of its affinity for the dextran backbone of the Superdex matrix (11, 14) . Analysis of purified human placental GAA by silver stained SDS- 14) . As shown in Fig. 1B , analysis of the Superose 6 fractions by SDS-PAGE demonstrates the 19-and 10-kDa polypeptides co-elute with the 76-and 70-kDa proteins at an apparent molecular weight of 75,000 Da, suggesting they are physically associated.
Characterization of Recombinant Human GAA Precursor and Processing Intermediates
It has been shown previously that recombinant CHO cells can be engineered to secrete the 110-kDa precursor form of human GAA into tissue culture media (25) . In addition to the 110-kDa precursor form, recombinant CHO cells also release proteolytically processed forms of GAA into the media by an undetermined mechanism. In Fig of the processed forms suggest a higher affinity for the matrix, which is consistent with previous reports that the 76-/70-kDa species has a Km for glycogen which is sevenfold to tenfold lower than the 110-kDa precursor (16, 17) .
Characterization of Recombinant Human GAA Precursor and Processing Intermediates by Mass Spectroscopy and Amino-terminal Micro-sequencing
To fully characterize GAA processing, we utilized a combination of MALDI-TOF mass spectroscopy, amino-terminal micro-sequencing, capillary LC/MS, and capillary LC/MS/MS of tryptic peptide maps. This allowed us to determine the amino-and carboxyl-terminus for each polypeptide and the structure of the N-glycans. The results of these analyses are summarized in When the processing intermediates, containing predominantly 95-and 76-kDa species by reduced SDS-PAGE ( Fig. 2A, lane 3) were analyzed unreduced by MALDI-TOF, major species with masses of ~103.5-and ~83.6-kDa were observed. After reduction, masses of ~99.8-and ~79.7-kDa were observed indicating a consistent mass shift of ~3.9-kDa, consistent with an interchain disulfide bond.
Analysis of human placental GAA by reduced SDS-PAGE ( Table I .
Modification of N-glycans during GAA Maturation
The GAA precursor contains seven consensus sites for N-glycosylation which are all utilized. In recombinant GAA on average these sites are occupied by 5-6 complex type glycans and 1-2 high-mannose type glycans. In contrast GAA expressed in human placenta contains predominantly high-mannose type glycans (18) . In either case, the newly synthesized glycans each contain about 9-11 hexoses/hexosamines and have an average molecular mass of ~2000 Da.
By mass spectroscopy the recombinant precursor contains ~14,000 Da of carbohydrate indicating an average of ~10 monosaccharides per glycan ( 
Identification of Subunits with Antipeptide Specific Antibodies
To independently evaluate the model for GAA maturation derived from mass spectroscopy; polyclonal, monoclonal, and antipeptide antibodies were generated to the following peptide sequences QQGASRPGPRDAQAHPGR (amino acids 57-74),
VPTQCDVPPNSRFDCAP (amino acids 78-94), and IKDPANRRYEVPLETPRV (amino acids
183-200) as described in "Experimental procedures." The resulting affinity purified antiserum are described as anti-GAA 57-74, anti-GAA 78-94, and anti-GAA 183-200; respectively.
Additionally, a goat polyclonal antibody to placental GAA (gt anti-GAA) and a monoclonal antibody to the 70-kDa polypeptide (GAA 1) were generated as described in "Experimental
Procedures."
As shown in (Fig. 3A, lanes 7-9) . This revealed the presence of a 10-kDa polypeptide in the intermediate and mature GAA samples (Fig. 3A, lane 8-9 ). These antibodies were helpful to understand the order of the cleavage events as shown in 2) which migrated slower than the precursor in Fig. 4 A, lane 1. The difference in mobility is due to glycosylation differences between HP-rhGAA precursor and rhGAA precursor (data not shown).
The blot shown in Fig. 4A was then probed with the antipeptide specific antibody for the 3.9-kDa polypeptide (amino acids 78-94) as shown in Fig. 4B . The antibody detected the 95-, and 76-kDa polypeptides in the absence of β-mercaptoethanol (Fig. 4B lanes 5-6) . The samples were run on a 4-20% SDS-PAGE as shown in Fig. 4C . We were not able to detect the 3.9-kDa fragment when run under reducing conditions, however, when the samples were not reduced an ~14-kDa polypeptide was observed (Fig. 4C lane 6) . The ~14 kDa polypeptide is comprised of the 3.9-kDa polypeptide disulfide bonded to the previously observed 10-kDa polypeptide.
GAA Exists as a Complex in Other Organisms
To determine if cleaved polypeptides are associated with GAA in other tissues, we purified endogenous hamster GAA from CHO cells. To our knowledge hamster GAA had never previously been isolated from a cultured cell line. The purification is described in detail in "Experimental Procedures." Silver stain SDS-PAGE analysis of hamster GAA revealed a predominant protein with an apparent molecular mass of 70-kDa (Fig. 4) . The 70-kDa protein was isolated by reverse phase chromatography and the amino-terminus was micro-sequenced.
The determined amino-terminal sequence, APSQLYSVEFSEEPF, is highly homologous to the amino-terminus for the human 70-kDa mature enzyme from amino acid positions 204-218 (APSPLYSVEFSEEPF).
Recombinant 110-kDa human precursor GAA, GAA purified from placenta, and hamster GAA purified from CHO cells were compared by SDS-PAGE (Fig. 5A, lanes 1-3) . Unlike placenta GAA, only the 70-kDa species was present in the highly purified preparation of hamster GAA from CHO cells. Western blot analysis was performed on hamster GAA with anti-GAA 183-200 (Fig. 5B, lane 1,3 ) and gt anti-GAA (Fig. 5B, lanes 2,3) . The blots reveal the 19-kDa and 10-kDa fragments are present in a highly purified preparation of hamster GAA from CHO cells. The presence of these subunits in highly purified GAA preparations from human placenta and CHO cells demonstrates that the formation and association of these subunits is not tissue or species specific.
The 19-kDa polypeptide in CHO preparations appears as a doublet. The cDNA for human GAA encodes for 2 glycosylation sites in the 19-kDa fragment. To determine if carbohydrate differences are responsible for the observed doublet, human placenta GAA and hamster GAA were denatured and digested with endoglycosidase H (Endo H) and peptide: Nglycosidase F (PNGase F). PNGase F is an amidase that cleaves between the innermost GlcNac and asparagine residues of high mannose, hybrid and complex oligosaccharides from N-linked glycoproteins (26) . Endo H is a glycosidase that cleaves the chitibiose core of high mannose and some hybrid oligosaccharides from N-linked glycoproteins (26) Endo H digestion did not have any affect on the 19.4-kDa polypeptide from human placenta or hamster GAA (Fig. 5C, lanes 1,   2, and 6 ). This suggests the carbohydrate is not high mannose-type. However PNGase F digestion decreased the apparent size of the 19.4-kDa polypeptide for both human placenta and hamster GAA (Fig. 5C, lanes 3, 4, 7, and 8) . The 19-kDa doublet in the hamster preparation was reduced to a single band, which suggests glycosylation differences are responsible for the doublet.
Proteolytic Processing of 110-kDa Precursor after uptake in Fibroblasts
To directly demonstrate the proteolytic processing of GAA in the cell proceeds via the pathway described, we utilized M6P-receptor mediated endocytosis of GAA precursor and a GAA deficient fibroblast cell line (GM00248) derived from a Pompe patient. To increase the amount of GAA internalized HP-rhGAA was used. The protein sequence of HP-rhGAA is identical to rhGAA precursor but differs in that the N-glycoyslation of HP-rhGAA contains 7-11
M6P groups per molecule of GAA. This was determined by LC/MS/MS. The evidence for this will be described elsewhere (manuscript in preparation). At the designated time points, cell lysates were prepared and analyzed by western blotting, using anti-GAA 57-74 (Fig. 6A) , a monoclonal antibody to the 70-kDa polypeptide (Fig. 6B) , and an anti-GAA 183-200 (Fig. 6C) .
In Fig. 6A only the GAA precursor standard is identified by anti-GAA 57-74. Fragments containing this sequence are not identified in any of the lysate derived samples. This is consistent with rapid release of this peptide upon internalization. In Fig. 6B , the same blot probed with monoclonal antibody GAA1 shows the conversion of the 110 kDa precursor to the transient 95 kDa intermediate followed by slower processing to the 76 kDa and 70 kDa forms.
DISCUSSION
It is well known GAA is synthesized as a 110 kDa precursor of 952 amino acids yet exists in lysosomes as major species of 76-and 70-kDa. It is generally agreed that the conversion from the 110 kDa to the 76-and 70-kDa is a result of proteolytic processing at both the amino-and carboxyl-termini. However, the structure of the 76-and 70-kDa mature forms of the enzyme has not been determined. Furthermore, the details and sequence of the processing steps is incomplete. In this study, we demonstrate fully processed GAA, consists of four associated polypeptides all derived from the GAA precursor. The ability to determine the structure of each fragment, using sensitive mass spectroscopic techniques, allows us to propose the model for GAA maturation which is shown in Fig. 7 and supported by Table I .
The GAA predicted primary translation product of 952 amino acids containing seven Nglycans is probably present only transiently and was not detected. The first proteolytic processing step is likely cleavage between amino acids 28 and 29 by signal peptidase, again the product of this cleavage was not detected. The first precursor identified in this study, contains amino acids 57-952 apparently resulting from a proteolytic cleavage between amino acids 56 and 57 ( Fig. 7 and Table I Interestingly there was no evidence that the three proteolytic processing steps could occur in any order except that proposed in our model. Had these cleavages occurred in a different order additional intermediates would have been formed which were not observed. The understanding that GAA maturation proceeds through a series of discrete, ordered steps may also have application as the basis for diagnostic tests for GSDII. In particular the identification of the fragment with masses of 3,927-, 10,392-, and 19,447-Da might be a sensitive indicator GAA is present and maturation has proceeded successfully. Additionally, the detection of such polypeptides could be used to monitor enzyme replacement therapy of Pompe disease.
The association of GAA's proteolytically cleaved fragments is not unique for lysosomal enzymes. The lysosomal alpha-mannosidase enzyme is synthesized as a single-chain precursor which is processed into three glycopeptides of 70-, 42-, and 15-kDa. The 70-kDa glycopeptide is further partially proteolysed into three more peptides that are joined by disulfide bridges (27) .
The previously described GAA2 allele (D91N) (23, (28) The maturation process is not dependent on an active GAA enzyme. A patient with infantile glycogenosis type II was found to be homozygous for a E521K substitution (30) . When COS cells were transfected with constructs containing the E521K mutation, the GAA was inactive and GAA maturation was prevented. However, when E521 was changed to E521Q, maturation of GAA was restored while there was still a loss of activity.
Since mature GAA consists of four polypeptides, this may have implications in treating GSDII. One current strategy for treating GSDII is to use enzyme replacement therapy. Using GAA -/-knockout mice (31, 32) , several groups have attempted enzyme replacement therapy with precursor and mature forms of recombinant GAA. Recombinant human 110-kDa precursor GAA purified from the milk of transgenic mice and rabbits demonstrated a therapeutic effect in knockout mice (17, 33) . Analysis of the tissues revealed the 110-kDa precursor from the rabbit milk and mouse milk was converted to the 76-kDa lysosomal form. Neither enzyme preparation appeared to be converted significantly to the 70-kDa form. Another study reported using the mature form of GAA (the composition was not described) to reverse muscle weakness in a knockout mouse (34) . Our improved understanding of the processing pathway may help us develop more effective second generation candidates for enzyme replacement therapy.
Sequences of five human family 31 glucohydrolases; GAA, maltose isoamylase (MGAM), sucrose isomaltase (SIM), glucosidase II (G2AN), and neutral α-glucosidase C (GANC) (35) ; have all been aligned using Clustal W (Fig. 8 ) (30) . Since the maltase isoamylase and sucrose isomaltase sequences have undergone duplication and contain two active sites, they have been divided into the amino-and carboxyl-terminal ends. Aligned in this fashion, the active site (WIDMNE) and many of the cysteines have been conserved. Sequences lost from GAA during processing are indicated in reverse bold. It is apparent from the alignment that GAA, MGAM and SIM are most closely related while G2AN contains a number of insertions and deletions reducing the overall homology. GAA is the only family 31 enzyme which is found in the lysosome and is known to undergo proteolytic maturation/processing. Interestingly, two of the four sequences removed during processing are found in the only two insertions in the GAA sequence relative to the family 31 consensus. It will be interesting in the future to determine how these sequences alter GAA structure and function. 9) . B, blots of P, I, and M, were probed with monoclonal antibody GAA1. The same blot was then probed with an affinity purified goat polyclonal antibody raised against GAA purified from human placenta (lanes 4-6). The blot was then probed with anti-GAA 183-200 (lanes 7-9). All blots were developed as described under "Experimental Procedures." Fig. 4 . Identification of a disulfide bound 3.9-kDa polypeptide.
All panels are reduced and nonreduced SDS-PAGE western blots loaded with the same samples as in Fig. 3 . Panels A and B are from a 6% acrylamide gel and panel C is from a 4-20% acrylamide gel. A, precursor (P), intermediate (I), and mature GAA (M) were probed with anti-GAA 57-74, monoclonal antibody GAA1 (lanes 4-6) . B, the blot shown in A was probed with anti-GAA 78-94 (lanes 1-6) . C, the blot from a 4-20% SDS-PAGE gel was probed with anti-GAA 78-94. All blots were developed as described under "Experimental Procedures." 
